Uj lehetöség a faktorhiányos, az antitest okozta és a thrombocyta eredetü vérzékenység kezelésében: a rekombináns aktív VII-es faktor koncentrátum.

Translated title of the contribution: New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recombinant Factor VIIa, a new therapeutic tool to treat severe bleeding caused by inhibitory haemophilia cases, some cases of thrombocytopenia and thrombocytopathy (e.g. severe type III von Willebrand disease) receives growing attention in clinical practice. Exogeneous FVIIa-in a supraphysiological concentration (clearly over 6 U/ml) seems to be able to generate quickly and safely (without thrombotic side effects) thrombin--the final enzyme of clotting--in physiological, or pathological conditions. A concise review about the possible mechanisms of action, indications, monitoring and clinical experience gained sofar with FVIIa is given in this report.

Translated title of the contributionNew possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate
Original languageHungarian
Pages (from-to)2255-2258
Number of pages4
JournalOrvosi hetilap
Volume139
Issue number38
Publication statusPublished - Sep 20 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate'. Together they form a unique fingerprint.

  • Cite this